High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan

International Journal of Cancer

Volumn 138, Issue 2, 2016, Pages 380-385

  Amayiri, Nisreen ^a   Tabori, Uri ^b,c   Campbell, Brittany ^b   Bakry, Doua ^b   Aronson, Melyssa ^d   Durno, Carol ^b,d   Rakopoulos, Patricia ^b   Malkin, David ^b   Qaddoumi, Ibrahim ^e   Musharbash, Awni ^a   Swaidan, Maisa ^a   Ouffet, Eric ^b   Hawkins, Cynthia ^b   Al Hussaini, Maysa ^a  

^a KING HUSSEIN CANCER CENTER   (Jordan)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Division of Neurosurgery   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

biallelic mismatch repair deficiency; caf au lait macules; consanguinity; high grade glioma; low income countries

Indexed keywords

ADOLESCENT; BRAIN NEOPLASMS; CANCER GRADING; CHILD; COLORECTAL NEOPLASMS; FEMALE; GENETICS; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; JORDAN; KAPLAN MEIER METHOD; MALE; MISMATCH REPAIR; MORTALITY; NEOPLASTIC SYNDROMES, HEREDITARY; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; JORDAN; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM GRADING; NEOPLASTIC SYNDROMES, HEREDITARY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84955643861     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29724     Document Type: Article

References (17)

1. Bakry D, Aronson M, Durno C, et al., Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 2014; 50: 987-96.
2. Wimmer K, Kratz CP., Constitutional mismatch repair-deficiency syndrome. Haematologica 2010; 95: 699-701.
3. Wimmer K, Kratz CP, Vasen HF, et al., Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J Med Genetics 2014; 51: 355-65.
4. Grover S, Syngal S., Risk assessment, genetic testing, and management of Lynch syndrome. J Natl Comprehensive Cancer Network 2010; 8: 98-105.
5. Sehgal R, Sheahan K, O'Connell PR, et al., Lynch syndrome: an updated review. Genes 2014; 5: 497-507.
6. O'Regan T, Chau K, Tatton M, et al., Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel. N Z Med J 2013; 126: 70-7.
7. Bougeard G, Olivier-Faivre L, Baert-Desurmont S, et al., Diversity of the clinical presentation of the MMR gene biallelic mutations. Familial Cancer 2014; 13: 131-5.
8. Marton E, Feletti A, Orvieto E, et al., Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature. J Neurolog Sci 2007; 252: 144-53.
9. Vu TM, Liubinas SV, Gonzales M, et al., Malignant potential of pleomorphic xanthoastrocytoma. J Clin Neurosci 2012; 19: 12-20.
10. Tabori U, Shlien A, Baskin B, et al., TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 2010; 28: 1995-2001.
11. Tabori U, Baskin B, Shago M, et al., Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010; 28: 1345-50.
12. Shlien A, Campbell BB, de Borja R, et al., Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genetics 2015; 47: 257-62.
13. Stoffel EM, Mangu PB, Gruber SB, et al., Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 2015; 33: 209-17.
14. Rutz HP, de Tribolet N, Calmes JM, et al., Long-time survival of a patient with glioblastoma and Turcot's syndrome. Case report. J Neurosurg 1991; 74: 813-5.
15. Hamilton SR, Liu B, Parsons RE, et al., The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332: 839-47.
16. Durno CA, Aronson M, Tabori U, et al., Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 2012; 59: 652-6.
17. Wick W, Platten M., Understanding and targeting alkylator resistance in glioblastoma. Cancer Discov 2014; 4: 1120-2.